Check Claims Before You Publish

Scientific-strength analysis (evidence-first)

1. Productivity and impact: The supplied profile (16 papers, 211 citations, h=7) is compatible with an early- to mid-career researcher who contributes to collaborative clinical and translational oncology studies; total citations are modest but non-trivial — impact concentrated in clinical-trial and multidisciplinary consortium outputs, which often accrue citations more slowly than basic-science breakthroughs.
2. Topical breadth: Titles show a mix of clinical trials/secondary analyses in non–small-cell and small-cell lung cancer, radiotherapy trials, pooled analyses, and computational/spatial transcriptomics preprints — indicating breadth across clinical oncology, radiation oncology, and computational methods. Breadth can be a strength if methodological rigor is maintained but presents blindspots if expertise is spread too thinly.
3. Authorship roles & reproducibility: Many titles (e.g., cooperative-group trials, pooled analyses, Alliance/CALGB/Cancer and Leukemia Group B studies) suggest multi-author, multi-center collaborations; such work is valuable but often dilutes individual contribution signal and requires close attention to role (first/last/corresponding author) for credit. Reproducibility for clinical trials is generally high when using trial registries and public datasets; computational/method papers require code/data for verification — not all entries show OA code/data links in the provided list.
4. Name ambiguity risk: Bibliographic databases (OpenAlex) list multiple distinct 'Xiaofei Wang' profiles with widely different metrics (h up to 49, works_count much larger). Without disambiguation (ORCID, institutional affiliation), bibliometrics are unreliable. This is supported by OpenAlex multiple-match data (see citation).

Evidence / citation for ambiguity and caution:

OpenAlex Xiaofei Wang matches

Strengths (supported by titles/metadata)

• Engagement in large cooperative-group clinical trials and pooled analyses (valuable for translational impact and patient-centered endpoints).
• Interdisciplinary reach bridging clinical oncology and computational spatial-omics (shows ability to work across wet lab/clinical and computational teams).
• Presence on contemporary high-visibility topics (immune checkpoint neoadjuvant trials, spatial transcriptomics methods) — increases potential future impact if sustained.

Weaknesses & red flags

• Low absolute citation counts (211 total) and modest h-index (7) relative to field leaders — suggests growing but not yet established citation impact.
• Name-disambiguation uncertainty — critical limitation for bibliometric interpretation (see OpenAlex citation above).
• Limited metadata on author position and contribution in multi-author clinical trials — reduces ability to assess independent scientific leadership.
• Some computational/spatial-omics preprints in the dataset are recent (2025–2026) and may not have fully available code/data or independent replication yet — reproducibility must be checked per paper.

Practical suggestions (to strengthen author scientific profile)

1. Obtain and display a persistent identifier (ORCID) and consistent institutional affiliation to remove name ambiguity in bibliographic databases.
2. For computational/method papers, provide fully documented code, data access links, and reproducible notebooks to increase reuse and citations.
3. Where possible, pursue senior/lead authorship on methods or translational studies to signal independent leadership.
4. Curate a public author page (GitHub/ORCID/Google Scholar) that clearly links the specific 16 papers and their author positions to avoid conflation with other researchers of the same name.

What would change this evaluation?

• Definitive disambiguation: providing ORCID or institutional profile connecting the 16 papers to a single person would allow accurate bibliometrics and likely change impact interpretation.
• Availability of open data/code and evidence of independent leadership (corresponding/last-author papers) would raise the scientific-quality assessment and reproducibility confidence.
• Independent external validations or prospective multi-center adoption of computational methods (e.g., HARMONIC or FOCUS-style tools) would significantly boost novelty/usefulness scores.

Representative evidence that supports mixed strength + need for disambiguation:

FOCUS spatial-transcriptomics model

HARMONIC histology-aware CCC method